Kaplan, FatihTopal, Erdem2024-08-042024-08-0420230041-4301https://doi.org/10.24953/turkjped.2022.386https://search.trdizin.gov.tr/yayin/detay/1178377https://hdl.handle.net/11616/92713Background. Myasthenia gravis is a chronic, autoimmune disease with muscle weakness. Acetylcholinesterase inhibitors are used in the symptomatic treatment of the disease. Allergic reaction to pyridostigmine bromide is rare. In the literature, no allergic reaction to pyridostigmine bromide has been reported in the pediatric population. Case. A 12-year-old female patient diagnosed with myasthenia gravis consulted our clinic with the complaint of urticaria due to pyridostigmine bromide. The oral challenge test performed with pyridostigmine bromide was positive. As the patient was required to be continue pyridostigmine bromide with no suitable alternatives, it was decided that the patient had to be desensitized to pyridostigmine. During and after the desensitization protocol, no reaction was observed. Conclusions. In this report, a successful desensitization protocol for pyridostigmine bromide in a child with myasthenia gravis is discussed.eninfo:eu-repo/semantics/openAccessallergydesensitizationmyasthenia gravispyridostigmine bromideArticle6523263293711469810.24953/turkjped.2022.3862-s2.0-85159178702Q31178377WOS:000982312900016Q4